Source: International Congress 2019 – Treatment of airway diseases in primary care
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Cazzola (Rome, Italy), L. Calzetta (Rome, Italy), E. Puxeddu (Rome, Italy), M. Matera (Naples, Italy), P. Rogliani (Rome, Italy). Efficacy of erdosteine, carbocysteine, and N-acetylcysteine in COPD: a comparative analysis. 729

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety of adding erdosteine in acute exacerbations of COPD (AECOPD): a comparative analysis with the standard treatment Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 Mucoactive drugs Source: Eur Respir Rev 2009; 19: 127-133 Year: 2010 Treatment of COPD: comparing the effects of inhaled steroids with N-acetylcysteine Source: Eur Respir J 2005; 26: Suppl. 49, 295s Year: 2005 Effect of aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) on exacerbations in moderate-to-severe COPD: Pooled analysis of two studies Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts Year: 2019 Persistency of antioxidant/antiinflammatory effects of erdosteine treatment in COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Free triple combination of glycopyrronium, indacaterol and ICS improves lung function and dyspnoea versus free double combination of indacaterol and ICS in patients with COPD: A post-hoc analysis from the GLOW6 study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Long-term use of antioxidant mucolytic erdosteine is especially beneficial in patients with more severe COPD Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Roflumilast in the treatment of COPD: A pooled safety analysis Source: Annual Congress 2010 - COPD: management Year: 2010 Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: A 1-year study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 The Bronchitis Randomized On NAC Cost-Utility Study (BRONCUS): hypothesis and design Source: Eur Respir J 2001; 17: 329-336 Year: 2001 Lung function, pharmacokinetics, and tolerability of indacaterol maleate and acetate in asthma patients Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 The effects of a crossover treatment with inhaled corticosteroids and N-acetylcysteine on lung function parameters in COPD-patients Source: Eur Respir J 2004; 24: Suppl. 48, 342s Year: 2004 48-week administration of olodaterol QD via Respimat® vs placebo and formoterol BID in patients with COPD: Pooled safety analysis Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Efficacy and safety of montelukast sodium on adult bronchial asthma in a multicentre comparative double-blind clinical study with pranlukast hydrate Source: Eur Respir J 2002; 20: Suppl. 38, 107s Year: 2002 Efficacy and safety of montelukast sodium on adult bronchial asthma in a multicenter comparative double-blind clinical study with pranlukast hydrate Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001 Comparative efficacy of umeclidinium/vilanterol versus LABA/LAMA therapies in COPD: A network meta-analysis Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Efficacy and safety of erdosteine in COPD: Results of a 12-month prospective, multinational study Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Efficacy of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomized controlled phase 3 trial Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 A double blind placebo controlled study to assess the effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients using novel biomarkers Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014